Hydrocodone (Vicodin, Norco, Zohydro ER) is a Schedule II opioid analgesic and historically the most prescribed opioid in the United States. It is most commonly dispensed in combination with acetaminophen (APAP) for acute pain. Hydrocodone is a mu-opioid receptor agonist activated in part by CYP2D6 to the more potent hydromorphone. Critical safety concerns include respiratory depression, physical dependence, and — for combination products — acetaminophen hepatotoxicity from exceeding daily APAP limits. Combining hydrocodone with gabapentin dramatically increases overdose risk beyond what either drug causes alone.
Hydrocodone
Uses & FDA Indications
Hydrocodone combination products (with acetaminophen) are FDA-approved for management of pain severe enough to require an opioid analgesic for which alternative treatments are inadequate. Extended-release hydrocodone formulations (Zohydro ER, Hysingla ER) are approved for around-the-clock management of pain requiring continuous opioid treatment.
Hydrocodone was historically the most prescribed drug of any class in the United States when combination products were Schedule III (requiring only a phone prescription). The 2014 rescheduling to Schedule II imposed stricter prescribing requirements — written or electronic prescriptions only, no automatic refills, no phone prescriptions — which contributed to a measurable decline in prescribing volume.
Some hydrocodone formulations historically included antitussive (cough-suppressing) indications, though these products have largely been removed from the market or reformulated.
BLACK BOX WARNING: Hydrocodone products carry FDA black box warnings for addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially children); neonatal opioid withdrawal syndrome; and dangerous interactions with benzodiazepines and CNS depressants. Combination products carry an additional warning for acetaminophen-related hepatotoxicity.
How It Works
Hydrocodone is a semisynthetic opioid derived from codeine. It acts as a full mu-opioid receptor agonist, producing analgesia through inhibition of ascending pain pathways, altered pain perception at the cortex, and reduced emotional response to pain via limbic system modulation. Opioid receptor activation also causes respiratory depression, euphoria, constipation, and pupillary miosis.
Hydrocodone's analgesic activity is attributed both to the parent drug and its active metabolite. CYP2D6 converts a portion of hydrocodone to hydromorphone (Dilaudid), which is significantly more potent. Patients who are CYP2D6 poor metabolizers (approximately 7–10% of Caucasians) produce less hydromorphone and may have reduced analgesic response. Ultra-rapid metabolizers may experience exaggerated effects.
Acetaminophen (APAP) in combination hydrocodone products does not have opioid properties — it works through a distinct mechanism to enhance analgesia. However, acetaminophen is responsible for the most critical safety constraint on these products: total daily APAP intake from all sources must not exceed 4,000 mg (3,000 mg in at-risk patients). Patients often do not realize that OTC medications like Tylenol PM, NyQuil, and many cold/flu formulas also contain acetaminophen.
Side Effects
Common
- Constipation — occurs in nearly all patients; does not develop tolerance; requires bowel regimen (stimulant laxative, not just fiber or stool softener alone)
- Nausea and vomiting — common at initiation, often improves with time
- Sedation and cognitive dulling — impairs driving and complex tasks
- Dizziness and lightheadedness
- Pruritus — histamine-mediated itching
- Miosis — pinpoint pupils; a reliable pharmacodynamic sign of opioid effect
Serious
- Respiratory depression — life-threatening; the primary cause of opioid overdose death; risk amplified by benzodiazepines, gabapentinoids, alcohol, and other CNS depressants
- Acetaminophen hepatotoxicity (combination products) — acute liver failure and death from exceeding APAP limits; risk increased by alcohol use, malnutrition, and pre-existing liver disease
- Opioid use disorder — physical dependence develops with regular use; addiction is a distinct neurobiological condition with compulsive use despite harm
- Serotonin syndrome — risk when combined with serotonergic agents; hydromorphone metabolite may contribute
- Adrenal insufficiency — rare; with prolonged opioid therapy
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Benzodiazepines (alprazolam, diazepam, clonazepam, lorazepam) | Synergistic CNS and respiratory depression. Opioid-benzodiazepine co-prescribing is associated with a 3.86-fold increased risk of opioid overdose death. | Critically High — FDA black box warning; avoid concurrent use when possible |
| Gabapentin and Pregabalin | Synergistic respiratory depression disproportionate to each drug alone. Studies demonstrate dramatically increased overdose mortality risk with opioid-gabapentinoid combination. | High — avoid combination; if both necessary, monitor respiratory function closely |
| CYP2D6 Inhibitors (fluoxetine, paroxetine, bupropion, quinidine) | Reduce conversion of hydrocodone to hydromorphone, potentially decreasing analgesic efficacy without reducing opioid side effects. | Moderate — monitor for reduced efficacy; may require dose reconsideration |
| CYP3A4 Inhibitors (ketoconazole, ritonavir, clarithromycin) | Increase hydrocodone plasma levels by reducing metabolism, raising risk of adverse effects and overdose. | High — monitor closely; consider dose reduction |
| Alcohol | Additive CNS and respiratory depression. Alcohol also causes hepatotoxicity that compounds acetaminophen liver toxicity risk in combination products. | High — avoid entirely; dual hepatotoxic risk with APAP formulations |
| MAO Inhibitors | Risk of serotonin syndrome and unpredictable potentiation of opioid CNS effects. | Critically High — contraindicated; avoid for 14 days before and after MAOI use |
Warnings & Contraindications
Contraindications
- Significant respiratory depression in an unmonitored setting
- Acute or severe bronchial asthma without monitoring/resuscitation availability
- Known or suspected gastrointestinal obstruction
- Hypersensitivity to hydrocodone or acetaminophen (in combination products)
- Concurrent MAO inhibitor use or use within 14 days
Acetaminophen Hepatotoxicity Risk
Acetaminophen is processed by the liver via sulfation and glucuronidation at therapeutic doses, with a small fraction going through CYP2E1 to a toxic metabolite (NAPQI) that glutathione neutralizes. In overdose — or with chronic alcohol use, malnutrition, or liver disease — glutathione is depleted and NAPQI accumulates, causing hepatocellular necrosis. Patients taking hydrocodone/acetaminophen products for chronic pain must actively monitor total daily acetaminophen intake from all sources. Clinicians should advise patients to check all OTC product labels for acetaminophen content.
Physical Dependence and Withdrawal
Physical dependence is a predictable pharmacological consequence of regular opioid use and does not constitute addiction. Abrupt discontinuation of hydrocodone after regular use causes opioid withdrawal: anxiety, restlessness, yawning, lacrimation, rhinorrhea, diaphoresis, piloerection, muscle aches, insomnia, nausea, vomiting, and diarrhea. Withdrawal is highly uncomfortable but rarely dangerous in otherwise healthy adults. Tapering under medical supervision is strongly recommended.
Check for hydrocodone interactions with gabapentin, benzodiazepines, and other medications.
Check Drug Interactions →Frequently Asked Questions
What is the difference between Vicodin and Norco?
Vicodin and Norco both contain hydrocodone combined with acetaminophen (APAP), but in different ratios. Vicodin typically contains 5 mg hydrocodone with 300 mg acetaminophen. Norco formulations contain hydrocodone (5, 7.5, or 10 mg) with 325 mg acetaminophen. Both are now generic and widely available. The key clinical distinction is the acetaminophen content — patients taking multiple tablets per day must track their total daily acetaminophen intake from all sources to avoid hepatotoxicity. The FDA recommends no more than 4,000 mg of acetaminophen per day for healthy adults (3,000 mg or less for those with liver disease or alcohol use).
Why is gabapentin dangerous with hydrocodone?
Gabapentin (Neurontin) and hydrocodone have a synergistic — not merely additive — interaction on respiratory depression. Studies have shown that the combination dramatically increases the risk of fatal opioid overdose beyond what either drug causes alone. Gabapentin's mechanism of action at voltage-gated calcium channels appears to potentiate opioid-induced respiratory depression in a way that is disproportionate to the sum of individual risks. The FDA has issued warnings about this combination, and several states have moved to schedule gabapentin as a controlled substance partly due to this dangerous interaction. Pregabalin carries the same risk.
Can hydrocodone cause liver damage?
Hydrocodone itself does not directly damage the liver, but acetaminophen in combination products like Vicodin and Norco absolutely can. Acetaminophen (APAP) hepatotoxicity is the leading cause of acute liver failure in the United States. Toxicity occurs when acetaminophen is taken in amounts exceeding the liver's capacity to process it safely — typically above 4,000 mg/day in healthy adults, or lower in those who drink alcohol regularly, have liver disease, or are malnourished. Patients taking hydrocodone/acetaminophen combination products must account for acetaminophen from all sources, including OTC medications like Tylenol, NyQuil, and many cold/flu products.